Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis

Masarone, Mario; Troisi, Jacopo; Aglitti, Andrea; Torre, Pietro; Colucci, Angelo; Dallio, Marcello; Federico, Alessandro Di; Balsano, Clara; Persico, Marcello

doi:10.1007/s11306-020-01756-1

Cited by 43 publications

(44 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Emerging evidence has proposed the potential use of metabolomic approaches to search for new non-invasive biomarkers of NAFLD [39]. In particular, plasma FAs levels in NAFLD subjects have been assessed in several lipidomic studies [40][41][42][43].…”

Section: Circulating Fas As Potential Biomarkers Of Nafldmentioning

confidence: 99%

The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update

Hliwa

Ramos‐Molina

Łaski

et al. 2021

IJMS

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is a major public health problem worldwide. NAFLD (both simple steatosis and steatohepatitis) is characterized by alterations in hepatic lipid metabolism, which may lead to the development of severe liver complications including cirrhosis and hepatocellular carcinoma. Thus, an exhaustive examination of lipid disorders in the liver of NAFLD patients is much needed. Mass spectrometry-based lipidomics platforms allow for in-depth analysis of lipid alterations in a number of human diseases, including NAFLD. This review summarizes the current research on lipid alterations associated with NAFLD and related complications, with special emphasis on the changes in long-chain and short-chain fatty acids levels in both serum and liver tissue, as well as in the hepatic expression of genes encoding the enzymes catalyzing lipid interconversions.

show abstract

Section: Circulating Fas As Potential Biomarkers Of Nafldmentioning

confidence: 99%

The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update

Hliwa

Ramos‐Molina

Łaski

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Furthermore, the L-alanine:pyruvate ratio was significantly correlated with BMI (R = 0.37, p = 0.01) even after adjustment for HOMA-IR and aminotransferase concentrations (β ± SE: 0.42 ± 0.18; p = 0.02). Six studies by Bhupathiraju et al [14], Feldman et al [15], Männisto et al [11], Stechemesser et al [12], Troisi et al [16], and Masarone et al [17] showed an increased concentration of branched-chain amino acids (BCAAs) in obese and NASH patients. Bhupathiraju et al [14], while investigating the metabolomic profiles associated with distinct dietary patterns among a sample of Asian Indians living in the United States, found that western/nonvegetarian dietary pattern was positively associated with a high concentration of BCAAs.…”

Section: Metabolism Of Amino Acids and Derivativesmentioning

confidence: 99%

“…A significant increase in the BCAA isoleucine was also observed by Troisi et al [16] in the saliva collected from paediatric obese patients compared to normal-weight subjects. Masarone et al [17], in a recent study from 2021, showed how the BCAAs increased with the progress of the disease severity from steatosis disease to NASH, and NASH-cirrhosis. As for BCAA, the amino acid glutamate was found significantly increased in NAFLD patients by Lovric et al [18] and Stechemesser et al [12], whereas Sookoian et al [13] were the only ones to identify an increased concentration of the amino acid kynurenine associated with serum concentrations of aminotransaminases and with BMI and HOMA-IR.…”

Section: Metabolism Of Amino Acids and Derivativesmentioning

confidence: 99%

See 1 more Smart Citation

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

Several differential panels of metabolites have been associated with the presence of metabolic syndrome and its related conditions, namely non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This study aimed to perform a systematic review to summarize the most recent finding in terms of circulating biomarkers following NAFLD/NASH syndromes. Hence, the research was focused on NAFLD/NASH studies analysed by metabolomics approaches. Following Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guidelines, a systematic search was conducted on the PubMed database. The inclusion criteria were (i) publication date between 2010 and 2021, (ii) presence of the combination of terms: metabolomics and NAFLD/NASH, and (iii) published in a scholarly peer-reviewed journal. Studies were excluded from the review if they were (i) single-case studies, (ii) unpublished thesis and dissertation studies, and (iii) not published in a peer-reviewed journal. Following these procedures, 10 eligible studies among 93 were taken into consideration. The metabolisms of amino acids, fatty acid, and vitamins were significantly different in patients affected by NAFLD and NASH compared to healthy controls. These findings suggest that low weight metabolites are an important indicator for NAFLD/NASH syndrome and there is a strong overlap between NAFLD/NASH and the metabolic syndrome. These findings may lead to new perspectives in early diagnosis, identification of novel biomarkers, and providing novel targets for pharmacological interventions.

show abstract

“…Although several pharmacological options are currently available, lifestyle modifications and metformin remain the first-line therapy in adolescence[ 17 ]. In this perspective, new insights for T2D treatment have recently emerging from omics studies[ 18 - 21 ]. Indeed, this intriguing field (including metabolomics, proteomics, genomics and lipidomics) has currently provided evidence for a pathogenic role in several metabolic diseases[ 22 - 25 ].…”

Section: Introductionmentioning

confidence: 99%

Omics era in type 2 diabetes: From childhood to adulthood

Passaro¹,

Marzuillo²,

Guarino³

et al. 2021

WJD

View full text Add to dashboard Cite

Parallel to the dramatic rise of pediatric obesity, estimates reported an increased prevalence of type 2 diabetes (T2D) already in childhood. The close relationship between obesity and T2D in children is mainly sustained by insulin resistance (IR). In addition, the cardiometabolic burden of T2D including nonalcoholic fatty liver disease, cardiovascular disease and metabolic syndrome is also strictly related to IR. Although T2D pathophysiology has been largely studied in an attempt to improve therapeutic options, molecular mechanisms are still not fully elucidated. In this perspective, omics approaches (including lipidomics, metabolomics, proteomics and metagenomics) are providing the most attractive therapeutic options for T2D. In particular, distinct both lipids and metabolites are emerging as potential therapeutic tools. Of note, among lipid classes, the pathogenic role of ceramides in T2D context has been supported by several data. Thus, selective changes of ceramides expression might represent innovative therapeutic strategies for T2D treatment. More, distinct metabolomics pathways have been also found to be associated with higher T2D risk, by providing novel potential T2D biomarkers. Taken together, omics data are responsible for the expanding knowledge of T2D pathophysiology, by providing novel insights to improve therapeutic strategies for this tangled disease. We aimed to summarize the most recent evidence in the intriguing field of the omics approaches in T2D both in adults and children.

show abstract

Untargeted metabolomics as a diagnostic tool in NAFLD: discrimination of steatosis, steatohepatitis and cirrhosis

Cited by 43 publications

References 54 publications

The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update

The Role of Fatty Acids in Non-Alcoholic Fatty Liver Disease Progression: An Update

Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review

Omics era in type 2 diabetes: From childhood to adulthood

Contact Info

Product

Resources

About